In a remarkable development for diabetes patients, the price of Empagliflozin, a commonly prescribed diabetes medication, is poised to drop dramatically following its recent patent expiry. Indian manufacturers, including Mankind Pharma and Dr Reddy’s, are preparing to launch generic versions priced at only 20 to 30 per cent of current levels, significantly easing the financial burden on individuals managing diabetes.
Empagliflozin belongs to the SGLT-2 inhibitor class of medications. These drugs are essential for managing diabetes as they assist in lowering blood glucose by preventing the kidneys from reabsorbing glucose and instead facilitating its excretion through urine. Initially, their use was primarily for patients with kidney ailments, but they are now a first-line treatment for all diabetics. Dr Ambrish Mithal, a leading endocrinologist, highlights that a staggering 80% of newly diagnosed patients at his clinic are now prescribed these medications.
The price of the diabetes drug Empagliflozin is set to decrease significantly following its patent expiry, allowing several manufactures to introduce generic versions. This move could help reduce drug costs for diabetes patients by 20-30%. The SGLT-2 inhibitors class is crucial for managing diabetes, especially in patients with kidney complications, with Empagliflozin showing benefits like weight management and reduced risk of hypoglycemia.
In conclusion, the recent patent expiry of Empagliflozin heralds a new era of affordability and availability for diabetes treatments in India. With prices set to significantly drop, patients can expect reduced monthly drug bills and improved access to essential medication. This landmark change not only enhances financial accessibility but also promises better health outcomes through effective blood sugar management.
Original Source: indianexpress.com
